How To Safely Handle Your Antibody Drug Conjugate

Antibody drug conjugates (ADCs) have a highly specific mechanism of action, a distinct advantage in challenging oncology indications. But there is an additional layer of complexity when it comes to their manufacture: ensuring the safe handling of these highly potent and highly toxic substances.

ADCs are biological drugs that comprise a highly toxic payload joined to an antibody with a linker moiety. They are commonly treated as highly potent because of the toxicity of the payload, which is typically active at a very low dose. As a result, there are strict requirements for containment during their manufacture. For a CDMO, specialized in-house occupational toxicology and industrial hygiene expertise is essential to ensure the safe handling of the ADCs they are developing.

In a recent webinar hosted by Lonza, “How to Safely Handle Your Antibody Drug Conjugate,” experts from the multinational CDMO company explored the key factors involved in ensuring the safe handling of ADCs, including toxicological assessment, risk assessment, best practices for containment, and occupational hygiene monitoring.